Investigational Agent Could Change Treatment of HER2-positive Metastatic Gastric Cancer

Researchers are hoping to find a new alternative to traditional chemotherapy to help treat HER2-positive metastatic gastric cancer, with later line treatments providing limited results which also take a toll on already fragile patients.┬áResults of the phase II DESTINY-Gastric01 trial showed trastuzumab deruxtecan can improve overall response and survival rates, while also avoiding some of the…